On June 25, 2019, BenchSci announced an additional investment from Google’s Gradient Ventures increasing its funding to $27.2 million. This investment will be used to expand BenchSci’s team and office to meet the growing demand from pharmaceutical companies for its biomedical AI technology.
BenchSci is a biomedical artificial intelligence (AI) technology company based in Toronto, and the world leader in AI-assisted antibody selection. BenchSci’s biomedical AI technology allows scientists to run more successful experiments to accelerate drug discovery.
Gradient Ventures is Google’s AI-focused venture fund. By investing and connecting early-stage startups with Google’s resources, innovation, and technical leadership in artificial intelligence, they are able to assist founders build transformational AI companies.
Osler, Hoskin & Harcourt LLP advised BenchSci with a team led by Chad Bayne and consisting of Justin Dharamdial, Gary Marshall, Jeremy Lin and Sahil Chopra (Emerging & High Growth Companies).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Associate, Emerging and High Growth Companies, Toronto
Partner, Emerging and High Growth Companies, Toronto
Associate, Emerging and High Growth Companies, Toronto
Partner, Emerging and High Growth Companies, Toronto
